Related Experiment Videos
[Venous thromboembolism in pregnancy].
P Laurent1, G Cellarier, A Cugulière
1Service de Cardiologie, Hôpital d'Instruction des Armées Ste Anne, Toulon. fplaurent@yahoo.com
Presse Medicale (Paris, France : 1983)
|February 22, 2000
Summary
Pregnancy increases the risk of venous thromboembolism, posing diagnostic and treatment challenges. Low-molecular-weight heparins (LMWH) are often used despite lacking official approval, highlighting the need for further clinical trials.
Area of Science:
- Obstetrics and Gynecology
- Hematology
- Pharmacology
Context:
- Pregnancy is a high-risk state for venous thromboembolism (VTE).
- Diagnosing VTE in pregnant women requires radiation-sparing imaging.
- Anticoagulant therapy must consider fetal teratogenic risks.
Purpose:
- To review the challenges in diagnosing and managing venous thromboembolism during pregnancy.
- To discuss current treatment options, including continuous infusion heparin and low-molecular-weight heparins (LMWH).
- To highlight the need for further research into optimal VTE prevention and treatment in pregnant patients.
Summary:
- Venous thromboembolism (VTE) is a significant concern during pregnancy due to physiological changes.
- Current management involves careful diagnostic imaging and anticoagulant therapy, balancing maternal and fetal safety.
- While continuous infusion heparin is validated, low-molecular-weight heparins (LMWH) are frequently used off-label due to practical advantages, though further clinical trials are essential.
Impact:
- Informs clinical practice regarding VTE management in pregnant individuals.
- Identifies gaps in evidence for optimal anticoagulant strategies.
- Emphasizes the necessity of future clinical trials to establish definitive treatment guidelines for VTE prevention and therapy in pregnancy.